Bioceltix, a publicly traded biotechnology company with a veterinary profile, received shareholder support for an issue of up to 457,000 shares during its Extraordinary General Meeting.
The company plans to raise approximately PLN 45 million, which will allow it to complete the construction of a large-scale pharmaceutical production facility and secure its financial position for the coming months.
Bioceltix is leading the way in biotechnology, developing innovative medicines for companion animals. The company is already on the European Medicines Agency (EMA) registration path, with applications for marketing authorization pending for BCX-EM for equine arthritis, and BCX-CM-J for canine osteoarthritis – this product has the potential to become the world’s first veterinary medicine containing canine stem cells.
Wrocław, October 9, 2025 – Shareholders passed a resolution to increase the company’s share capital through the issue of new ordinary bearer shares of series N, with the preemptive rights of existing shareholders waived in full. The Series N shares will be offered for subscription in a private placement, without a prospectus, exclusively to Alternative Solution ASI and Kvarko Group ASI. In September, the company entered into an investment agreement with these two major shareholders, under which they will offer for sale in a public offering up to 457,000 of their shares admitted to trading on the Warsaw Stock Exchange. The agreement also provides for the possibility of Alternative Solution ASI selling an additional 120,000 shares within the ABB framework, without committing to contributing funds to a capital increase in the company, with the priority being to raise funds for the new issue. The investment agreement also stipulates the intention to set the minimum price at PLN 95. The offering will be conducted through mBank S.A. and Trigon Dom Maklerski, with ccgroup acting as the company’s financial and IR advisor.
“I am very pleased that our shareholders understand and support the strategy we are implementing. They expressed this by adopting the issue resolution.” This means we won’t have to slow down, both in terms of registering our drugs and building a pharmaceutical plant. This is especially important in the latter case. We’re getting closer to launching a product for canine osteoarthritis, and our current plant will only be able to provide modest production capacity of up to 30,000 doses per year. Therefore, building a new, large-scale plant is a priority. We should soon be able to resolve all the missing permits, work will begin in earnest, and costs will start to accumulate. The capital raised from the issue will provide us with security for one of the most important stages of our company’s development,” says Paweł Wielgus, member of the Bioceltix management board.
The Global Potential of Polish Biotechnology
Representatives of the Wrocław-based biotech emphasize that the global animal health market is currently on an upward trend, driven by a fundamental shift in people’s attitudes towards four-legged pets and the increasing number of them. A simultaneous increase in the incidence of inflammatory and autoimmune diseases, such as osteoarthritis and atopic dermatitis, is predicted among pets. These diseases are classified as lifestyle diseases in the animal kingdom and require modern and safer treatment methods. Bioceltix’s stem cell-based biologics, in addition to their symptomatic effects, also exhibit causal effects, thus targeting the underlying causes of the disease, making them an effective alternative to traditional, currently used therapies.
MACHINE TRANSLATION